Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from I-MAB ( (IMAB) ).
On August 1, 2025, I-MAB announced its expected cash and cash equivalents, along with short-term investments, totaling $165.6 million as of June 30, 2025. These preliminary financial results are subject to adjustments upon the completion of the company’s quarter-end financial processes, highlighting I-MAB’s financial stability and potential strategic positioning within the biopharmaceutical industry.
The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-MAB is a biopharmaceutical company that focuses on the development of innovative biologics for the treatment of cancer and autoimmune diseases. The company is positioned in the healthcare industry, with a market focus on providing advanced therapeutic solutions.
Average Trading Volume: 586,816
Technical Sentiment Signal: Buy
Current Market Cap: $158.7M
Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.